Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10517940 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4DRD2HRH3HTR3A | |
| SCHEMBL14761301 | 0.81 | HTR1A (0.65) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL13469510 | 0.80 | HTR1A (0.79) | HTR1ADRD2 | |
| SCHEMBL3679755 | 0.79 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR7HTR6 | |
| SCHEMBL647772 | 0.79 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR7HTR6 | |
| SCHEMBL9600934 | 0.79 | HTR1A (0.69) | HTR1ADRD2HTR7HRH3HTR3A | |
| SCHEMBL14761873 | 0.79 | HTR1A (0.69) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL9602546 | 0.78 | HTR1A (0.67) | HTR1ADRD2HTR7HRH3HTR3A | |
| SCHEMBL9822980 | 0.78 | HTR1A (0.67) | HTR1ASLC6A4DRD2HTR7HRH3 | |
| SCHEMBL14028451 | 0.77 | HTR1A (0.79) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR1A 3/4885SLC6A4 41/4885DRD2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.